Novartis AG with ticker code (NVS) have now 4 analysts in total covering the stock. The consensus rating is pointing to ‘Buy’. The target price High/Low ranges between 113.5 and 103 calculating the mean target price we have $107.13. Now with the previous closing price of $96.47 this would indicate that there is a potential upside of 11.1%. The 50 day MA is $87.06 while the 200 day moving average is $85.22. The company has a market capitalization of $208,188m. You can visit the company’s website by visiting: https://www.novartis.com
The potential market cap would be $231,193m based on the market consensus.
Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company operates through two segments: Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and physicians. It also provides cardiovascular, ophthalmology, neuroscience, immunology, hematology, and solid tumor products. The Sandoz segment develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
The company has a dividend yield of 3.56% with the ex dividend date set at 9-3-2023 (DMY).
Other points of data to note are a P/E ratio of 30.98, revenue per share of 23.76 and a 6.45% return on assets.
